Royalty Report: Drugs, Cannabis, Delivery – Collection: 305318


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Cannabis
  • Delivery
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 305318

License Grant
The agreement provides for the Licensor’s grant of a non-exclusive right and sub-license to use certain Licensor technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa.

The term of the agreement ends the earlier of (i) July 15, 2020 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year.

License Property
The technology is for eluting patches.

Licensor has acquired an exclusive, worldwide license for an eluting transmucosal patch platform (ETP) for non-invasive drug delivery in the cannabis field.

Licensor is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems.

Field of Use
The Technology is centered around an eluting patch platform (“ETP”), which is a bio adhesive, transmucosal orally dissolving thin film system. The platform allows for actives loaded onto the ETP to be absorbed by the buccal mucosa into the body.

The license is for transmucosal delivery of legal medical or recreational cannabis (other than in the field of oral care) and cannabinoids.

Licensor’s oral patch has been shown in clinical studies to be a safe, accurate and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability.
The OralTabs product contains 21mg of full spectrum CBD in each tab and is available in 5 and 30 pack boxes in a wild mint berry flavor with additional packet sizes, formulations and flavors planned for later on in the year.

With concern growing over vaping and the numerous incidents now being reported, Licensee’s oral patch, provides a safe alternative delivery platform that can be utilised to deliver cannabinoids directly into the body without the harmful side effects of smoking or vaping, and with quicker onset and greater bioavailability than ingestibles.  Licensee is dedicated to the production, research, cultivation, processing and distribution of medicinal cannabis oil to pharmaceutical companies worldwide.

IPSCIO Record ID: 241951

License Grant
Canadian Licensor hereby grants to Israeli Licensee an exclusive license to exploit the Licensor solely as necessary to develop, manufacture, market, use, sell, offer for sale, import, export, commercialize and distribute the Licensed Products (the License).
License Property
Licensed Product relates to an orally dissolved film containing CBD, as an active material, for medical treatment.

Licensed Product shall mean Licensor’s patch described below hereto in combination with Cannabidiol (CBD) for medical or recreational cannabis, where latter permitted for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted (other than in the field of oral care) or any other product exploiting the Licensee Cannabis IP for the transmucosal delivery of medicinal or recreational cannabis, where latter permitted.

Description of Patch – A “Eluting Transmucosal Patch Platform (ETP)” for non-invasive drug delivery.

Licensor Patents shall mean those patents and patent applications listed below, as well as patents issuing therefrom, and any substitutions, divisions, continuations, continuations-in-part (but only to the extent that they cover the same invention claimed in the foregoing), reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like, and any provisional applications, of any such patents or patent applications.

Patent(s)/Patent Application(s)
1. WO 2012/104834 A1
New oral dissolving films for insulin administration, for treating diabetes.
filed on December 2011. National Phase at Israel and the USA.
2. WO 2010/135053 A2
Dual and single layer dosage forms.
Issued USA patent on April 28, 2015.
3. PCT/IL 2017/050845
Adhesive Oral dissolved Films in Managing Oral Care.
PCT on 31 July 2017.

Field of Use
This agreement pertains to the drug industry relating to Cannabis.

IPSCIO Record ID: 269589

License Grant
The Israeli Licensor, the technology transfer company of the University, hereby grants the Israel Company an option to receive an exclusive, sublicensable, worldwide royalty-bearing license to Licensors interest in the Study Results in the field of Systemic and local, tran-dermal and trans-mucosal delivery of cannabinoids using Exudates based formulations.
License Property
The Feasibility Study Program relates to the development of a Cannabis patch and can the prospect of the cannabis patch be considered a platform, depending on its composition and the character of the ingredients included within it.
Field of Use
This agreement pertains to the drug industry relating to Cannabis.

IPSCIO Record ID: 204556

License Grant
Licensor grants to Licensee exclusive Worldwide rights to BiPhasix Transdermal Drug Delivery Technology for the delivery and commercialization of Cannabinoids, Cannabidiol (CBD), and Tetrahydrocannabinol (THC) based products.
License Property
The term “Product” shall mean any pharmaceutical product, development candidate for human or animal use arising out of the collaboration based on the BiPhasix CBD Intellectual Property Rights.

Biphasixâ„¢ is a needle-free, noninvasive, particulate drug delivery system suitable for intra- and transdermal delivery of drugs.

BiPhasixâ„¢ can entrap and transport pharmaceutical products through the skin to achieve therapeutic benefit in a wide range of indications. Studies have shown that BiPhasixâ„¢ can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes. In addition, this proprietary technology can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal, ocular, and rectal.

Field of Use
The rights are to BiPhasixâ„¢ transdermal drug delivery technology for the development and commercialization of Cannabinoids, Cannabidiol (CBD) and Tetrahydrocannabinol (THC) products.

The Company will use for the delivery and commercialization of cannabinoid, cannabidiol and tetrahydrocannabinol-based products.

IPSCIO Record ID: 27852

License Grant
The Licensee announced that it has entered into a non-binding Letter of Intent to license the Canadian Licensor's proprietary RapidMistâ„¢ drug delivery technologies for the delivery of medicinal and recreational cannabis derived products into the bloodstream through the buccal membrane.
License Property
The RapidMistâ„¢ drug delivery platform administers medications directly into the mouth as a metered dose spray for rapid absorption by the buccal mucosa.
Field of Use
The Licensee is a provider of consulting and advisory services to licensed medical and recreational marijuana operators and retail dispensaries within the United States.

Licensor's most advanced product in development using RapidMistâ„¢ is Generex Oral-lynâ„¢, an insulin spray product for the treatment of diabetes mellitus.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.